[Effective therapy option in the late phase of Parkinson disease: subcutaneous apomorphine].
D000978:Antiparkinson Agents / Q000008:administration & dosage*; D001058:Apomorphine / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D018491:Dopamine Agonists / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007279:Injections, Subcutaneous; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy / Q000451:nursing*
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D001058:Apomorphine